However, pancreatic cancer, as an extremely malignant tumor with a poor prognosis, has low immunogenicity, and common immune checkpoint blockers such as CTLA-4 or PD-1 inhibitors are ineffective for pancreatic cancer patients (51). Here, CTLA4 is linked to neoplasm.